Core Viewpoint - Immuneering Corporation has announced a clinical supply agreement with Eli Lilly for the evaluation of atebimetinib in combination with olomorasib in a Phase 2 trial targeting advanced non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations [1][2] Group 1: Clinical Development - The agreement supports the evaluation of Immuneering's lead product candidate, atebimetinib, a novel dual MEK inhibitor, in combination with olomorasib [1] - Immuneering is also evaluating atebimetinib in combination with Regeneron's anti-PD-1 therapy Libtayo in advanced NSCLC patients [1] - The combination aims to provide a vertical blockade of the RAS-MAPK pathway, potentially improving treatment outcomes in patients with limited options [3] Group 2: Product and Pipeline - Immuneering maintains global development and commercialization rights to atebimetinib [4] - The company is developing Deep Cyclic Inhibitors, with atebimetinib designed to improve durability and tolerability for MAPK pathway-driven tumors [5] - Atebimetinib is currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [5]

Core Viewpoint - Sensei Biotherapeutics is transitioning from early response-focused readouts to longer-term efficacy signals in its Phase 1/2 study of solnerstotug, which shows a favorable safety profile and potential for better patient adherence and outcomes [2][3] Clinical Program Highlights - Full data for the Phase 1/2 dose expansion cohort is expected by year-end 2025, with enrollment complete at 64 patients [6] - The ongoing trial evaluates solnerstotug as a monotherapy and in combination with cemiplimab in patients with advanced solid tumors [3] - Preliminary clinical data indicates favorable activity in PD-(L)1 resistant "hot" tumors, with solnerstotug well tolerated and no dose-limiting toxicities reported [6] Corporate Updates - Sensei's cash position was $28.6 million as of June 30, 2025, down from $41.3 million at the end of 2024, with expectations to fund operations into Q2 2026 [8] - Research and Development expenses decreased to $2.5 million in Q2 2025 from $4.6 million in Q2 2024, attributed to lower personnel and facility costs [9] - General and Administrative expenses also decreased to $2.7 million in Q2 2025 from $3.2 million in Q2 2024, primarily due to lower personnel costs [10] Financial Results - The net loss for Q2 2025 was $4.9 million, an improvement from a net loss of $7.1 million in Q2 2024 [10] - Total operating expenses for Q2 2025 were $5.2 million, down from $7.8 million in Q2 2024 [13]